Streetbeat News

Earnings

BKKT

Bakkt Holdings (BKKT) reported Q4 earnings with a loss of $(0.29) per share, missing the $(0.13) estimate by 123.08%, and a 76.61% improvement from last year's $(1.24) loss. Sales were $15.10M, missing the $15.25M estimate by 0.98%, marking a 3.21% decrease from last year's $15.60M.

Portfolio Pulse from Happy Mohamed

March 25, 2024 | 8:22 pm

REKR

Rekor Systems (NASDAQ:REKR) reported Q4 losses of $(0.16) per share, missing the $(0.10) estimate by 60%, and sales of $11.07M, beating the $10.72M estimate by 3.23%. This represents a 143.26% increase in sales compared to the same period last year.

Portfolio Pulse from Happy Mohamed

March 25, 2024 | 8:21 pm

AVTE

Aerovate Therapeutics reported a Q4 2023 GAAP EPS of $(0.74), missing the consensus estimate of $(0.70) by 5.71%.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:15 pm

SMTI

Sanara MedTech (NASDAQ:SMTI) reported Q4 earnings with losses of $(0.03) per share, surpassing the $(0.13) estimate, and sales of $17.69M, exceeding the $16.50M estimate. This represents significant improvements over the previous year.

Portfolio Pulse from Happy Mohamed

March 25, 2024 | 8:14 pm

REKR

Rekor Systems (NASDAQ:REKR) reported Q4 sales of $11.07M, surpassing the $10.72M estimate, marking a 143.26% increase from $4.55M in the same period last year.

Portfolio Pulse from Happy Mohamed

March 25, 2024 | 8:13 pm

QMCO

Quantum (QMCO) received a letter from Nasdaq regarding non-compliance with the $1.00 bid price requirement. The company also filed a Form 8-K, detailing an amendment to its term loan agreement to use asset disposition proceeds for debt reduction. Quantum is working to resolve delays in filing its Form 10-Qs due to re-evaluating standalone selling price under ASC Topic 606, aiming to be current with SEC financial reports by May 7, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:12 pm

VNRX

VolitionRx Limited (VNRX) reported a significant increase in cash and cash equivalents, totaling approximately $20.7 million as of December 31, 2023, compared to $10.9 million the previous year. The company also saw a 153% increase in revenue, reaching about $775,000 in 2023, and received $13.0 million in milestone payments from Heska Corporation in December 2023. However, net cash used in operating activities was $18.1 million for the year. VolitionRx will host a conference call on March 26, 2024, to discuss these financial highlights and other updates.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:11 pm

TMC

TMC Metals reported a Q4 2023 GAAP EPS loss of $(0.11), surpassing the analyst consensus estimate of $(0.16) by 31.25 percent.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:09 pm

STOK

Stoke Therapeutics announced promising Phase 1/2a end of study data for STK-001, showing significant reductions in convulsive seizure frequency in Dravet Syndrome patients. The data revealed 85% median reduction at 3 months and 74% at 6 months with 70mg doses. Open label extension studies showed durable seizure reductions and cognitive improvements over 12 months with 30mg and 45mg doses. STK-001 was well-tolerated, and the company plans to discuss registrational study design with regulatory agencies, aiming for initial doses of 70mg followed by 45mg. A webcast for analysts and investors is scheduled for 4:30 p.m. Eastern Time today.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:04 pm

EFTR

eFFECTOR Therapeutics reported its financial results for Q4 and the full year of 2023, highlighting a cash position of $18.4M as of December 31, 2023, with expectations to fund operations into Q1 of 2025. The company experienced a decrease in revenue, reporting zero for 2023 compared to $3.6M in 2022, primarily from grant revenue for COVID-19 treatment research. R&D expenses slightly decreased due to lower costs in the zotatifin program, offset by increased expenses in the KICKSTART trial for tomivosertib. G&A expenses also saw a reduction, and the company reported a net loss of $35.8M for the year.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:04 pm